Shares of nano-cap company Polyrizon Ltd. (PLRZ) surged over 200% on Wednesday morning after the company announced that it entered into a manufacturing agreement with Eurofins CDMO Amatsiaquitaine S.A.S, a European-based Good Manufacturing Practice (GMP) manufacturer.
PLRZ is currently trading at $3.1998, up $2.1498 or 204.8600%, on the Nasdaq. The stock opened its trading at $2.5000 after closing Tuesday at $1.0500. The stock has traded between $0.7700 and $3.4000 in the past 52-week period.
This collaboration will supply Clinical Trial Material (CTM) for Polyrizon's PL-14 allergy blocker, in preparation for a clinical trial that is expected to commence in 2025.
With this agreement, which was announced earlier this month, Polyrizon secures a reliable and compliant manufacturing source for the PL-14 clinical trial.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.